TScan Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

TScan Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 2.3% en 57.2% per jaar. De winst per aandeel zal naar verwachting groeien met 17.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -68.6% zijn.

Belangrijke informatie

2.3%

Groei van de winst

17.8%

Groei van de winst per aandeel

Biotechs winstgroei	27.1%
Inkomstengroei	57.2%
Toekomstig rendement op eigen vermogen	-68.6%
Dekking van analisten	Good
Laatst bijgewerkt	27 Aug 2024

Recente toekomstige groei-updates

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11

Recent updates

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18

Winst- en omzetgroeiprognoses

NasdaqGM:TCRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	10	-155	-104	-132	5
12/31/2025	7	-144	-102	-123	6
12/31/2024	7	-130	-93	-108	6
6/30/2024	12	-104	-75	-71	N/A
3/31/2024	15	-97	-70	-67	N/A
12/31/2023	21	-89	-65	-61	N/A
9/30/2023	17	-88	-58	-54	N/A
6/30/2023	16	-82	-82	-79	N/A
3/31/2023	17	-73	-74	-70	N/A
12/31/2022	14	-66	-71	-67	N/A
9/30/2022	13	-62	-70	-65	N/A
6/30/2022	12	-61	-67	-62	N/A
3/31/2022	11	-57	-66	-59	N/A
12/31/2021	10	-49	-59	-49	N/A
9/30/2021	8	-42	-51	-42	N/A
6/30/2021	6	-34	-43	-34	N/A
3/31/2021	3	-29	-14	-8	N/A
12/31/2020	1	-26	-7	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat TCRX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat TCRX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat TCRX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van TCRX ( 57.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van TCRX ( 57.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat TCRX binnen 3 jaar verliesgevend zal zijn.

TScan Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 60%

Price target increased by 7.5% to US$11.40

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus revenue estimates decrease by 22%, EPS upgraded

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Price target decreased to US$14.00

Recent updates

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

TScan Therapeutics, Inc Announces Board Changes

Consensus revenue estimates fall by 60%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Tscan Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Tcr-T Therapy for the Treatment of Solid Tumors

TScan Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

TScan Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.084643 million.

TScan Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.084643 million.

TScan Therapeutics, Inc. Announces Executive Changes

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.5% to US$11.40

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. Appoints Jason A. Amello as Chief Financial Officer

Tscan Therapeutics Appoints Jason A. Amello as Chief Financial Officer

Chairman of the Board recently bought US$142k worth of stock

Tscan Therapeutics, Inc. Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 At the 65Th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors

TScan Therapeutics, Inc. Announces Appointment of Justin Mccue, as Chief Technology Officer

New major risk - Share price stability

Consensus revenue estimates decrease by 33%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Tscan Therapeutics, Inc. Announces Management Appointments

New major risk - Financial position

High number of new and inexperienced directors

TScan Therapeutics, Inc. Announces Board Changes

Chairman of the Board recently bought US$100k worth of stock

TScan Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $139.995299 million.

TScan Therapeutics, Inc. Appoints Gavin MacBeath as A Member of the Board of Directors

TScan Therapeutics, Inc. Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Full year 2022 earnings: EPS and revenues miss analyst expectations

TScan Therapeutics, Inc. Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

TScan Therapeutics, Inc. Announces its 2023 Clinical Pipeline Plans

Tscan Therapeutics Presents Phase 1 Umbrella Trial in Progress on Ha-1 (Tsc-100) and Ha-2 (Tsc-101) At the 64Th American Society of Hematology Annual Meeting 2022

Price target decreased to US$14.00

Consensus revenue estimates increase by 19%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

TScan Therapeutics, Inc. Appoints Debora Barton to Serve as Chief Medical Officer, Effective July 5, 2022

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

TScan Therapeutics, Inc. Promotes Gavin Macbeath, Ph.D. to Chief Scientific and Operations Officer

Tscan Therapeutics, Inc. Announces Fda Clearance of Investigational New Drug Application for Tsc-101 for the Treatment of Hematologic Malignancies

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

President recently bought US$90k worth of stock

Consensus revenue estimates increase by 16%

TScan Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Senior VP & CFO recently bought US$51k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

TScan Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

President exercised options to buy US$236k worth of stock.

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

President recently bought US$96k worth of stock

TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven